1. Acknowledgement to Referees

   Acknowledgement to Referees 11 November 2019 Pages: 627 - 630

2. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials

   • Xavier Paliard
   • Olivier Rixe

   Current Opinion Open access 08 October 2019 Pages: 631 - 637

   

3. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options

   • Vivian Loo
   • Meghan Salgia
   • Sumanta K. Pal

   Review Article 08 October 2019 Pages: 639 - 645

   

4. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab

   • Hans-Christian Kolberg
   • Marco Colleoni
   • Vladimir Hanes

   Review Article Open access 16 October 2019 Pages: 647 - 656

   

5. PARP Inhibition in Cancer: An Update on Clinical Development

   • Esha Sachdev
   • Roya Tabatabai
   • Monica M. Mita

   Review Article 17 October 2019 Pages: 657 - 679

   

6. Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study

   • Susan Feyerabend
   • Fred Saad
   • Karim Fizazi

   Original Research Article Open access 21 November 2019 Pages: 681 - 688

   

7. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study

   • Jwa Hoon Kim
   • Sun Young Kim
   • Yong Sang Hong

   Original Research Article 25 September 2019 Pages: 689 - 697

   

8. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study

   • Laura M. Legué
   • Felice N. van Erning
   • Geert-Jan Creemers

   Original Research Article 17 October 2019 Pages: 699 - 705

   

9. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study

   • David Lang
   • Florian Huemer
   • Bernd Lamprecht

   Original Research Article Open access 25 October 2019 Pages: 707 - 717

   

10. Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study

    • Zhengquan Yang
    • Jialu Li
    • Chunming Ding

    Original Research Article 06 November 2019 Pages: 719 - 728

    

11. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice

    • Anna M. Czarnecka
    • Paweł Teterycz
    • Piotr Rutkowski

    Original Research Article 21 November 2019 Pages: 729 - 742

    

12. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab

    • Huezin H. Lim
    • Ashley M. Hopkins
    • Michael J. Sorich

    Short Communication 01 November 2019 Pages: 743 - 748

    

13. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer

    • Young-A Heo
    • Yahiya Y. Syed

    Adis Drug Evaluation 04 November 2019 Pages: 749 - 758

    

14. Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC

    • Sohita Dhillon
    • Yahiya Y. Syed

    Adis Drug Evaluation 14 November 2019 Pages: 759 - 768

15. Correction to: Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer

    • Y. Louise Wan
    • Puja Sapra
    • Peter L. Stern

    Correction Open access 03 October 2019 Pages: 769 - 769